Brief: Apollomics Inc. Receives FDA Orphan Drug Designation For Vebreltinib (Apl-101) For Treatment Of Non-Small Cell Lung Cancer With Met Genomic Tumor Aberrations
15/11/2022 13:15
Nov 15 (Reuters) - Maxpro Capital Acquisition Corp
JMAC.O :
* APOLLOMICS INC. RECEIVES FDA ORPHAN DRUG DESIGNATION FOR
VEBRELTINIB (APL-101) FOR TREATMENT OF NON-SMALL CELL LUNG
CANCER WITH MET GENOMIC TUMOR ABERRATIONS
Source text for Eikon: ID:nGNX7LddcS
Further company coverage: JMAC.O